Prescribing information (external link)

Hero banner. LUTATHERA® (lutetium [177Lu] oxodotreotide) logo.
Hero banner. LUTATHERA® (lutetium [177Lu] oxodotreotide) logo.

Mechanism of action

LUTATHERA® (lutetium [177Lu] oxodotreotide) is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.1

LUTATHERA® Summary of Product Characteristics (SmPC) can be found here

LUTATHERA® delivers SSTR2-targeted radiation directly to overexpressing malignant cells of GEP-NETs1

Based on pre-clinical data.

GEP-NETs strongly overexpress SSTR22

  • With a high affinity for SSTR2, LUTATHERA® is designed to deliver beta radiation directly to tumour cells, disrupting them from within1

  • The beta radiation is mostly contained within the tumour, limiting damage to neighbouring healthy cells1

Mechanism of action graphic in 4 stages detailing how LUTATHERA® is designed to deliver beta radiation directly to tumour cells, disrupting them from within.1

Stage 1

LUTATHERA® is infused into the bloodstream, where it targets and binds to malignant cells overexpressing SSTR2.1

Stage 2

LUTATHERA® is then internalised into the cell.3

Stage 3

In the cell, it delivers beta radiation, with an average tissue penetration of 0.67mm.1

Stage 4

The radiation disrupts the targeted tumour cell from within, with a limited effect on neighbouring normal cells.1

Page header image.

Dosing and administration

Dosing and administration
See more details
Hide details
Page header image

Safety profile

Safety profile
See more details
Hide details

GEP-NET, gastroenteropancreatic neuroendocrine tumour; RLT, radioligand therapy; SmPC, summary of product characteristics; SSTR, somatostatin receptor.

References

  1. LUTATHERA® Summary of Product Characteristics.

  2. Thundimadathil J. J Amino Acids 2012;2012:967347.

  3. Hennrich U & Kopka K. Pharmaceuticals (Basel) 2019;12(3):114.

 

UK | December 2025 | FA-11462531-1

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.